Download or read book Molecular Markers and Targeted Therapy for Hepatobiliary Tumors volume I A written by Yunfei Xu and published by Frontiers Media SA. This book was released on 2024-07-26 with total page 343 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatobiliary tumor, mainly including hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer, is a group of highly aggressive malignancies. Hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer have different biological characters, histopathological traits, and treatment strategies, but have similar clinical features such as silent early symptom and extremely poor prognosis. The diagnostic, predictive or prognostic tumor biomarkers of hepatobiliary cancers are in unmet need. In contrast to the poor outcome, the treatment options to hepatobiliary cancers are very limited. It is still controversial about the effects of chemotherapy and radiotherapy of hepatobiliary cancer. FDA-approved targeted drugs are only Sorafenib and Lenvatinib for hepatocellular carcinoma, and Pemigatinib for cholangiocarcinoma. Unfortunately, these drugs are only effective for 5%-30% patients. Therefore, more attention should be called upon on investigating effective biomarkers and drug targets, stratifying high-risk patients, guiding precise treatments, and developing therapeutic strategies for hepatobiliary cancers. This Research Topic aims at discussing the current knowledge and proceedings of diagnostic, predictive and prognostic tumor biomarkers in hepatobiliary cancer, and presenting the recent advances on new drug targets and potential targeted therapies of hepatobiliary cancer. We welcome submissions of Review, Mini-Review, Clinical Trial and Original Research articles covering, but not limited to, the following topics: 1. new diagnostic/prognostic factors, biomarkers and/or risk factors in hepatobiliary tumors 2. new drug targets, and oncogenic or tumor suppressive molecular mechanism of the novel targets 3. new intervention or targeted therapy in hepatobiliary tumors 4. new findings of bioinformatics or high-throughput methods such as mass spectrometry and genome-wide association studies or which may help screen the potential biomarkers of hepatobiliary tumors 5. clinical studies such as cohort study or RCT to identify new risks or treatment therapies in hepatobiliary tumors 6. basic, pharmacological, preclinical or clinical study of potential drugs targeting hepatobiliary tumors Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Download or read book Molecular Markers and Targeted Therapy for Hepatobiliary Tumors volume I B written by Yunfei Xu and published by Frontiers Media SA. This book was released on 2024-07-26 with total page 295 pages. Available in PDF, EPUB and Kindle. Book excerpt: Download the ebooks for this Research Topic: Volume I.A: ¦PDF¦ ¦EPUB Volume I.B: ¦PDF¦ ¦ EPUB Hepatobiliary tumor, mainly including hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer, is a group of highly aggressive malignancies. Hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer have different biological characters, histopathological traits, and treatment strategies, but have similar clinical features such as silent early symptom and extremely poor prognosis. The diagnostic, predictive or prognostic tumor biomarkers of hepatobiliary cancers are in unmet need. In contrast to the poor outcome, the treatment options to hepatobiliary cancers are very limited. It is still controversial about the effects of chemotherapy and radiotherapy of hepatobiliary cancer. FDA-approved targeted drugs are only Sorafenib and Lenvatinib for hepatocellular carcinoma, and Pemigatinib for cholangiocarcinoma. Unfortunately, these drugs are only effective for 5%-30% patients. Therefore, more attention should be called upon on investigating effective biomarkers and drug targets, stratifying high-risk patients, guiding precise treatments, and developing therapeutic strategies for hepatobiliary cancers. This Research Topic aims at discussing the current knowledge and proceedings of diagnostic, predictive and prognostic tumor biomarkers in hepatobiliary cancer, and presenting the recent advances on new drug targets and potential targeted therapies of hepatobiliary cancer. We welcome submissions of Review, Mini-Review, Clinical Trial and Original Research articles covering, but not limited to, the following topics: 1. new diagnostic/prognostic factors, biomarkers and/or risk factors in hepatobiliary tumors 2. new drug targets, and oncogenic or tumor suppressive molecular mechanism of the novel targets 3. new intervention or targeted therapy in hepatobiliary tumors 4. new findings of bioinformatics or high-throughput methods such as mass spectrometry and genome-wide association studies or which may help screen the potential biomarkers of hepatobiliary tumors 5. clinical studies such as cohort study or RCT to identify new risks or treatment therapies in hepatobiliary tumors 6. basic, pharmacological, preclinical or clinical study of potential drugs targeting hepatobiliary tumors Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Download or read book Targeted Therapies in Oncology Second Edition written by Giuseppe Giaccone and published by CRC Press. This book was released on 2013-10-21 with total page 500 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.

Download or read book Hepatocellular Carcinoma written by Yujin Hoshida and published by Springer. This book was released on 2019-08-05 with total page 366 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.

Download or read book Patient Derived Tumor Xenograft Models written by Rajesh Uthamanthil and published by Academic Press. This book was released on 2016-10-13 with total page 488 pages. Available in PDF, EPUB and Kindle. Book excerpt: Patient Derived Tumor Xenograft Models: Promise, Potential and Practice offers guidance on how to conduct PDX modeling and trials, including how to know when these models are appropriate for use, and how the data should be interpreted through the selection of immunodeficient strains. In addition, proper methodologies suitable for growing different type of tumors, acquisition of pathology, genomic and other data about the tumor, potential pitfalls, and confounding background pathologies that occur in these models are also included, as is a discussion of the facilities and infrastructure required to operate a PDX laboratory. Offers guidance on data interpretation and regulatory aspects Provides useful techniques and strategies for working with PDX models Includes practical tools and potential pitfalls for best practices Compiles all knowledge of PDX models research in one resource Presents the results of first ever global survey on standards of PDX development and usage in academia and industry

Download or read book Diagnosis and Management of Cholangiocarcinoma written by James H. Tabibian and published by Springer Nature. This book was released on 2021-05-28 with total page 589 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive, state-of-the-art overview of cholangiocarcinoma (CCA). The text is structured to effectively present a broad yet concise overview of bile duct cancer, its relevant definitions, classification schemata, clinical management tenets, translational (including molecular and cellular) facets, and future directions. The book features numerous high-yield illustrations and is authored by an eclectic range of renowned experts in various areas of CCA, reflecting the multidisciplinary nature of the field. Filling a critical gap in the field, Diagnosis and Management of Cholangiocarcinoma: A Multidisciplinary Approach is a valuable resource for clinicians and practitioners who treat patients with bile duct cancer.

Download or read book Immunotherapy of Hepatocellular Carcinoma written by Tim F. Greten and published by Springer. This book was released on 2018-08-22 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.

Download or read book WHO Classification of Tumours of the Digestive System written by F. T. Bosman and published by International Agency for Research on Cancer. This book was released on 2010-10-15 with total page 424 pages. Available in PDF, EPUB and Kindle. Book excerpt: "The WHO Classification of Tumours of the Digestive System presented in this book reflects the views of a Working Group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, December 10-12, 2009"--P. [5].

Download or read book Hepatobiliary Cancer written by Paul H. Sugarbaker and published by . This book was released on 2014-09-01 with total page 348 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Colorectal Cancer Liver Metastases written by Mauro Monteiro Correia and published by Springer Nature. This book was released on 2019-12-28 with total page 597 pages. Available in PDF, EPUB and Kindle. Book excerpt: Colorectal cancer is the third most commonly diagnosed condition in oncology, affecting around 1.23 million individuals per year, according to recent statistics. Of these patients, about 50% will develop liver metastases and approximately 20% will present a stage IV disease at diagnosis. These statistics make colorectal liver metastases (CLM) an issue of major importance in current oncology. The area of CLM is subject to great and continuous advances, as its pathophysiologic mechanisms are better understood and more therapeutic and surgical options are developed. Consequently, all professionals involved with the diagnosis, treatment and follow up of CLM should be kept up to date with the latest advances on the field, to provide high standard medical care to their patients. This book is designed to present the state-of-the-art in CLM management and, in doing so, to review the current evidence on CLM, discussing all important topics in the field. Coverage is broad and comprehensive, encompassing introductory topics (history, definitions, epidemiology, etc.), basic science subjects (molecular biology, genetics, dissemination process, etc.) and practical clinical topics (tumor behavior, diagnosis, drug therapy, radiation therapy, surgery, ablation, multidisciplinary teams, etc.). Although comprehensive on the coverage and selection of topics, each chapter is concise and objective, dissecting topics in a practical and direct format. Evidences and recommendations are included. Chapters display a brief introduction of the common knowledge, go straight to the detailed revision of the most recent years of the literature, and end with practical closing observations. This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases.

Download or read book Biomarkers and Immunotherapy of Hepatic Biliary Pancreatic Cancers written by Yunfei Xu and published by Frontiers Media SA. This book was released on 2024-02-29 with total page 349 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatic-biliary-pancreatic cancers, mainly including hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, are highly aggressive malignancies with few treatment options and poor prognoses. Effects of the traditional systemic treatments such as chemotherapy and radiotherapy, are quite limited to hepatic-biliary-pancreatic cancers. For the patients who suffer from hepatic-biliary-pancreatic cancer and lose the opportunity of radical surgery, few targeted drugs are available. Even for the drugs in clinical trial, potential drug targets and prognostic biomarkers for hepatic-biliary-pancreatic cancer are less studied compared to other common cancers such as lung cancer. Prognostic biomarker study is the initiation to explore new drug targets and revelation of the underlying mechanisms of tumor progression. Immunotherapy, especially PD1 or PD-L1 antagonists, has exhibited potent treatment effects on cancers. To date, many PD1 drugs are available for cancer treatment, and more than one hundred PD1 drugs are in clinical trial. However, how to screen out the sensitive patients and predict the efficacy of immunotherapy are still unsolved problems. Moreover, the predictive biomarkers and treatment guidelines of immunotherapy for hepatobiliary tumors are barely investigated.

Download or read book Hepatocellular Carcinoma written by Ahmed Kaseb and published by BoD – Books on Demand. This book was released on 2013-10-23 with total page 334 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatocellular carcinoma (HCC) develops as a consequence of underlying chronic liver disease, most commonly cirrhosis. Therefore, HCC management draws on the expertise of a range of medical specialists. Many components of current novel therapeutic modalities for HCC are discussed in the current version of the book within the framework of a multidisciplinary approach with special emphasis on emerging treatment approaches and research strategies. This book is the essential clinical guide for oncologists, hepatologists, surgeons, and all physicians and researchers involved in the care of patients with HCC. I would like to thank the authors for their significant efforts in bringing this edition to life. This book is a tribute to their continued dedication to improving HCC outcome.

Download or read book Hepato Pancreato Biliary Malignancies written by Cataldo Doria and published by Springer Nature. This book was released on 2022-09-30 with total page 859 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepato-Pancreato-Biliary cancers are increasing in incidence, with pancreatic cancer now accounting for the third most cancer deaths in the United States. Typically these malignancies, as a group, are managed by the same key providers comprising a multidisciplinary team. This book is intended to provide a comprehensive review of the current knowledge in the field of hepato-pancreato-biliary malignancies, focusing on the practical and clinical care of patients. We take the approach of combining the collective expertise of an interventional gastroenterologist and a hepato-pancreato-biliary surgeon to provide the readers with accurate, succinct, and pragmatic information needed to formulate the most appropriate treatment plan for their patients with the aim of the best possible outcome. Managing patients with these cancers continues to be challenging because of continued dismal survival rates. Each section in this text is written by experts in their respective field, summarizing the most state-of-the-art, contemporary diagnostic and therapeutic tools available in the field. We believe this book will prove to be an invaluable, comprehensive resource for all members of the multidisciplinary team caring for patients with hepato-pancreato-biliary malignancies.

Download or read book Drug Resistance and Immune Modulation New Issues in Cancer Systemic Therapy written by Yunpeng Hua and published by Frontiers Media SA. This book was released on 2022-05-27 with total page 140 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Combinational Immunotherapy of Cancer Novel Targets Mechanisms and Strategies written by Xuyao Zhang and published by Frontiers Media SA. This book was released on 2024-01-15 with total page 537 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapy, has revolutionized the paradigm in cancer treatment. However, the clinical outcome of immunotherapy varies considerably among patients and only a minority of patients achieve long-term clinical benefits. This is largely attributed to the fact that existing cancer immunotherapies, which concentrate on several classical targets (CTAL-4, PD-1/PD-L1, etc.) and limited types of immune cell populations (T cells), are insufficient to cope with the complexity of highly heterogeneous tumor microenvironment (TME). This calls for more efforts to not only expand our toolbox for manipulating anticancer immunity but also diversify our combinational strategies. To this end, it is urgent to deeper our understanding of cancer immunotherapy by using both experimental and computational methodologies from multi-scale perspectives: 1) novel targets from either tumor cells or non-tumor cells within TME (e.g., tumor intrinsic resistance drivers, new immune checkpoints, neoantigens), 2) in-depth characterization of more immune cell populations (e.g., macrophages, Tregs, B cells) and their interactions and dynamics within TME, 3) landscape of actionable targets in patient populations for combination design. These efforts will open the avenue of rational design of combinational immunotherapies, allowing researchers and clinicians to design novel targeting therapeutics or to optimally orchestrate combinatory strategies aiming to surmount resistance mechanisms and improve clinical outcomes.

Download or read book Endobronchial Ultrasound Guided Transbronchial Needle Aspiration EBUS TBNA A Practical Approach written by S.E. Monaco and published by Karger Medical and Scientific Publishers. This book was released on 2014-05-22 with total page 147 pages. Available in PDF, EPUB and Kindle. Book excerpt: This high-yield reference book focuses on the clinical, technical, and pathological aspects of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Its reviews cover all aspects of EBUS-TBNA, including the clinical perspective, technical aspects of the procedure, and cytomorphology of common and uncommon entities, as well as highlights diagnostic challenges. Each chapter features a multitude of full-color high-resolution images and includes key references to the current literature in the field. Additionally, reference tables and informative figures highlight the salient points. The book is unique in that it is written by experienced thoracic surgeons, pulmonary medicine physicians, and cytopathologists who use EBUS-TBNA in a large medical center. This publication is of interest to individuals learning and practicing cytopathology, in addition to clinicians practicing pulmonary/thoracic medicine or surgery. In short, it provides important pearls of wisdom to create a comprehensive reference for all physicians involved with EBUS-TBNA.

Download or read book Cancer and IgE written by Manuel L. Penichet and published by Springer Science & Business Media. This book was released on 2010-01-23 with total page 290 pages. Available in PDF, EPUB and Kindle. Book excerpt: Erika Jensen-Jarolim and Manuel L. Penichet 1. 1 Background Infectious diseases, being the major burden in the history of mankind worldwide th until the beginning of the 20 century, were important triggers in the understanding of immunological mechanisms. In contrast to infectious diseases, reports of all- gies and cancers were less common, but increased tremendously within the last century. Based on the US mortality data of the National Center for Health Statistics, Centers for Disease Control and Prevention 2009, a recent report from the American Cancer Society indicated that the number of cancer deaths increased approximately from 100,000 to 550,000 per year between 1930 and 2006, paralleling the increase of the total population during this period. Leading causes of death from cancer are lung and bronchus cancer, in men prostate cancer, and in women breast c- cer [1, 2]. Normalization to population size shows that the cancer death rate for most malignancies has been generally stable, although the mortality rate of certain malignancies, such as lung and bronchus cancer, has increased over the last 50 years [1-3]. In allergy, the situation is less clear, because for the time period around the turn of th the 19 century, only imprecise information is available. However, within the last 30 years the incidences of allergies has doubled not only in industrial countries, but in developing countries as well [4].